Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.45 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPN | P05981 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30193348 | 1.00 | NLRP3 (0.52) | NLRP3L3MBTL1ABL1METTL3METTL14 | |
| SCHEMBL7214903 | 0.90 | L3MBTL1 (0.49) | L3MBTL1ABL1NAMPTKDM4AGRM2 | |
| SCHEMBL29792562 | 0.90 | L3MBTL1 (0.49) | L3MBTL1ABL1NAMPTKDM4AGRM2 | |
| SCHEMBL6328558 | 0.87 | NQO2 (0.47) | NLRP3L3MBTL1NAMPTMAPTTDP1 | |
| SCHEMBL27525744 | 0.80 | NLRP3 (0.59) | NLRP3ABL1METTL3METTL14MAPT | |
| SCHEMBL6848416 | 0.80 | CYP2A6 (0.50) | NLRP3NAMPTMAPTTDP1GAA | |
| SCHEMBL22652435 | 0.80 | NLRP3 (0.46) | NLRP3L3MBTL1METTL3METTL14NAMPT | |
| SCHEMBL1912330 | 0.80 | L3MBTL1 (0.49) | L3MBTL1NAMPTKDM4AMAPTTDP1 | |
| SCHEMBL12481099 | 0.80 | NLRP3 (0.48) | NLRP3ABL1 | |
| SCHEMBL10210032 | 0.80 | ROCK2 (0.52) | L3MBTL1NAMPTKDM4AGRM2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-3931188-B1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| CN-113474340-A | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors | 勃林格殷格翰国际有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| CN-101006055-B | 3-substituted-5-and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase ie | AVENTIS PHARMA INC | 2011-06-22 | — | — | CN | disclosed |
| EP-1794122-B1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7923466-B2 | treating in a lengthening of circadian rhythm period with 6-aminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide; for treating central nervous system diseases and mood disorders, bipolar disorder and sleep disorders, with an enzyme inhibitor | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7629376-B2 | 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-31 | — | — | US | disclosed |
| CN-101006055-A | 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase iepsilon | AVENTIS PHARMA INC (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1794122-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006023467-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281099-B2 | Isoindolinone substituted indoles and derivatives as RAS inhibitors | NRAS, KRAS, RASSF5 | NLRP3 3790/4885L3MBTL1 2370/4885ABL1 47/4885 |
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK2A3, CSNK1G3, CSNK1G1 | NLRP3 4560/4885L3MBTL1 3403/4885ABL1 117/4885 |
| US-20220144810-A1 | NEW ISOINDOLINONE SUBSTITUTED INDOLES AND DERIVATIVES AS RAS INHIBITORS | NRAS, RASSF5, KRAS | NLRP3 3698/4885L3MBTL1 2427/4885ABL1 63/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | NLRP3 1799/4885L3MBTL1 4307/4885ABL1 211/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | NLRP3 1799/4885L3MBTL1 4307/4885ABL1 211/4885 |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK1G3, CSNK2A3, CSNK1E | NLRP3 4260/4885L3MBTL1 3902/4885ABL1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.